Background
Cloudbreak Therapeutics, LLC owns U.S. Patent No. 10,149,820, which covers compositions and methods for treating pterygium — an abnormal tissue growth on the surface of the eye. Allgenesis Biotherapeutics Inc. initiated inter partes review (IPR) of the patent before the Patent Trial and Appeal Board (PTAB). The core dispute before the Board involved whether certain claims of Cloudbreak’s patent were anticipated by Allgenesis’s own PCT (international patent) application.
PTAB ruled against Allgenesis, finding that Cloudbreak’s patent claims were entitled to the priority date of a provisional application that predated the Allgenesis PCT application. Because the Cloudbreak patent’s effective date came first, it could not be anticipated by the later-filed Allgenesis document. Allgenesis appealed to the Federal Circuit, but the threshold question was whether Allgenesis had standing under Article III of the U.S. Constitution to bring that appeal at all — a question the court resolved against Allgenesis without reaching the merits.
The Court’s Holding
The Federal Circuit dismissed Allgenesis’s appeal for lack of Article III standing. To invoke federal court jurisdiction, an appellant must demonstrate a concrete injury in fact, a causal connection between the injury and the conduct challenged, and redressability. Because IPR petitioners — unlike patent defendants — are not automatically in court defending against infringement claims, they must affirmatively show why they have a stake in the patent’s validity. The court found that Allgenesis failed to do so on either of the two theories it advanced.
First, Allgenesis argued that it faced a substantial risk of future infringement claims based on its research activities and product pipeline. The court rejected this because Allgenesis’s evidence of future activity was too vague and speculative. A petitioner must show concrete plans for specific future conduct — not just general research in a therapeutic area — that would create a real and imminent infringement risk. Generalized aspirations to develop products in a field covered by the patent do not suffice.
Second, Allgenesis argued that the adverse priority ruling in the IPR would have preclusive effect — through collateral estoppel — on future proceedings involving its own patent portfolio. The court rejected this theory as well, explaining that collateral estoppel does not attach to PTAB’s priority determinations made in the course of IPR. The priority ruling was a non-final, interlocutory-style finding within the IPR proceeding, not the kind of final judgment on a contested issue that gives rise to preclusive effect in subsequent litigation.
Key Takeaways
- IPR petitioners lack automatic standing to appeal adverse PTAB decisions; they must independently demonstrate a concrete Article III injury — typically by showing they face a real and imminent risk of infringement liability.
- Vague or aspirational product development plans in a therapeutic area are insufficient to establish the injury in fact needed for standing; petitioners need concrete evidence of specific planned activities that would infringe the challenged patent.
- PTAB priority determinations made during IPR proceedings do not have collateral estoppel effect in later proceedings, so an adverse priority ruling cannot serve as the injury supporting standing to appeal.
- Companies that petition for IPR without currently facing infringement threats should carefully assess their standing before investing in an appeal of an adverse PTAB ruling.
Why It Matters
Standing is an increasingly important gating issue in Federal Circuit IPR appeals. Because any member of the public can petition for IPR — not just defendants facing infringement suits — the Federal Circuit must police whether appellants have a genuine stake in the outcome. This case illustrates a trap that catches companies that use IPR proactively to clear patent obstacles from a competitive landscape: winning at the petition stage does not guarantee the ability to appeal an adverse final written decision.
For biotech and pharmaceutical companies in particular, the ruling has strategic implications. Companies often challenge competitor patents through IPR to protect future product development. But if the product pipeline is not sufficiently concrete at the time of appeal, the Federal Circuit may dismiss the challenge before the merits are ever heard. Companies should either ensure they have specific, documented product plans that could be threatened by the challenged patent, or consider whether to pursue parallel district court declaratory judgment proceedings that would independently establish standing. The decision also forecloses a creative but ultimately unsuccessful argument that adverse priority rulings create stand-alone preclusive harm — a theory that, if accepted, would have made standing available to virtually any IPR petitioner whose patent portfolio overlaps with the challenged technology.